Threatening clots in MGUS and myeloma

Blood

Volumn 115, Issue 24, 2010, Pages 4975-4976

  Ludwig, Heinz ^a   Delforge, Michel ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; THALIDOMIDE; VINCRISTINE;

ARTERY THROMBOSIS; COMORBIDITY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INCIDENCE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; STEM CELL TRANSPLANTATION; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 77956515928     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-276345     Document Type: Note

References (10)

1. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991-4998.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6): 585-593.
3. Broderick JP. Stroke trends in Rochester, Minnesota, during 1945 to 1984. Ann Epidemiol. 1993;3(5):476-479.
4. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948-954.
5. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 112(9): 3582-3586.
6. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423. (Pubitemid 351255436)
7. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost. 2007;33(4):339-349.
8. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003; 1(3):445-459.
9. Libourel EJ, Sonneveld P, van der Holt B, de Maat MPM, Leebek FWG. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study [published online ahead of print March 25, 2010]. Blood. doi:10.1182/blood-2009-12-257519.
10. Khorana AA, Streiff MB, Farge D, et al. Thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919-4926.